# US 2014/0370021 A1 · OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0370021 A1
- Document ID: US20140370021A1
- Status: Published application
- Kind: A1
- Application number: 13/918,782
- Filed: 2013-06-14
- Published: 2014-12-18
- Earliest claimed: 2013-06-14
- Assignees: Xencor, Inc.
- Inventors: Gregory Alan Lazar; Arthur J. Chirino; Wei Dang; John Desjarlais; Stephen K. Doberstein; Robert J. Hayes; Sher Bahadur Karki; Omid Vafa
- Web page: https://patentgrep.com/patent/US20140370021A1

## CPC

- C07K 16/2893: {against CD52}
- C07K 16/2887: {against CD20}
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.

## Claims

### Claim 1

A protein comprising an Fc variant of a human parent IgG1 Fc polypeptide, said Fc variant comprising a first amino acid substitution at position 243 and a second amino acid substitution at position 264 in the Fc region of said parent Fc polypeptide, wherein numbering is according to the EU index.

### Claim 2 (depends on 1)

The protein of claim 1, wherein said protein is an Fc fusion.

### Claim 3 (depends on 1)

The protein of claim 1, wherein said protein is an antibody.

### Claim 4 (depends on 3)

The protein of claim 3, wherein said antibody is selected from the group consisting of a human antibody, a humanized antibody, and a monoclonal antibody.

### Claim 5 (depends on 3)

The protein of claim 3, where said antibody comprises an engineered glycoform.

### Claim 6 (depends on 3)

The protein of claim 3, wherein said antibody has specificity for a target antigen selected from the group consisting of CD19, CD20, CD22, CD30, CD33, CD40, CD40L, CD52, Her2/neu, EGFR, EpCAM, MUC1, GD3, CEA, CA 125, IgE, HLA-DR, TNFalpha, MUC18, prostate specific membrane antigen (PMSA) and VEGF.

### Claim 7 (depends on 1)

The protein of claim 1, wherein said protein is an Fc fusion or antibody with specificity for a target antigen Her2/neu.

### Claim 8 (depends on 1)

A pharmaceutical composition comprising the protein of claim 1, further comprising a pharmaceutically acceptable carrier.
